A carregar...
Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo‐controlled phase 3 trial
Tofacitinib is an oral Janus kinase inhibitor. These post‐hoc analyses assessed tofacitinib efficacy and safety in Japanese patients with psoriasis enrolled in a 52‐week global phase 3 study. Patients received tofacitinib 5 mg, tofacitinib 10 mg or placebo twice daily (b.i.d.); placebo‐treated patie...
Na minha lista:
Publicado no: | J Dermatol |
---|---|
Main Authors: | , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
John Wiley and Sons Inc.
2017
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5697670/ https://ncbi.nlm.nih.gov/pubmed/28714180 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1346-8138.13956 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|